Background: Prior ischemic stroke or transient ischemic attack (TIA) is a high risk for thromboembolism in patients with nonvalvular atrial fibrillation (NVAF). To clarify rates of thromboembolic and hemorrhagic events, and target intensities of warfarin for secondary prevention, a subanalysis was performed using data from the J-RHYTHM Registry. Methods: Of 7937 outpatients with atrial fibrillation, 7406 with NVAF (men 70.8%, 69.8 ± 10.0 years) were followed for 2 years or until an event occurred. Event rates and effect of warfarin were compared between patients with (secondary prevention) and without (primary prevention) prior stroke/TIA.
Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia and is a major risk factor for cardiogenic embolism.
1,2 CHADS2 3 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, and history of stroke or transient ischemic attack (TIA)) or CHA2DS2-VASc scores 4 are widely used for risk stratification of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). A history of ischemic stroke or TIA carries a stronger risk for ischemic stroke than other components of these scores. 3, 4 Once patients suffer from cardiogenic embolism, their condition is mostly severe, and mortality can be higher as compared with other types of ischemic stroke. 5 In addition, cardiogenic embolism had a higher 10-year recurrence rate (75.2%) after the first event in the Hisayama study. 6 Therefore, prophylaxis with anticoagulation therapy is crucial for reducing AF-related ischemic stroke in patients with a history of stroke or TIA (stroke/TIA). Oral anticoagulation therapy with vitamin K antagonists, mainly warfarin, can reduce the risk of AF-related ischemic stroke by 60%-70%. 7, 8 However, information regarding the incidence of thromboembolic and hemorrhagic events in Japanese NVAF patients with a history of ischemic stroke/ TIA is still limited.
9,10 Therefore, we investigated the incidence of thromboembolic and hemorrhagic events in patients with and without a history of ischemic stroke/ TIA, using a post hoc analysis of the J-RHYTHM Registry. [11] [12] [13] Additionally, optimal anticoagulation intensities of warfarin for patients with a history of ischemic stroke/TIA were determined, although these had previously been determined using a small number of Japanese patients. 10 Because a target international normalized ratio (INR) of prothrombin time is different between NAVF patients aged younger than 70 and 70 years or older in the current Japanese guidelines, 14 we also investigated event rates in both age groups of younger than 70 and 70 years or older.
Methods

Study Design of the J-RHYTHM Registry
The J-RHYTHM Registry was a prospective, observational nationwide study. Study design and baseline characteristics have been reported in detail elsewhere. 11, 12 Briefly, the subjects were a consecutive series of outpatients with AF of any type, regardless of the use of antithrombotic drugs. Antithrombotic drugs and dosages were selected at the discretion of the treating cardiologists. Because no nonvitamin K antagonist oral anticoagulant (NOAC) was available when this registry was carried out in 2009, all anticoagulation therapies were performed with warfarin in this study. Patients with valvular AF, including mitral stenosis and mechanical prosthetic valves, 15 were excluded from this subanalysis.
Follow-Up and Definition of Endpoints
The patients were followed for 2 years, or until an endpoint, whichever occurred first. The thromboembolic endpoints consisted of symptomatic ischemic stroke, TIA, and systemic embolism. Major hemorrhage as the safety endpoint included intracranial hemorrhage, gastrointestinal hemorrhage, and others requiring hospitalization. All-cause mortality and cardiovascular mortality were also determined. If any event occurred during the follow-up period, the final clinical data, including INR at the time closest to the event, were collected. 11 The diagnostic criteria for each event have been described elsewhere.
11,12
Classification of Patients
Patients were divided into 2 groups, that is, the "primary" and "secondary" prevention groups, according to the history of ischemic stroke/TIA, and were divided further into 2 age groups of younger than 70 and 70 years or older. In addition, patients receiving warfarin were divided into 5 subgroups according to their INR (<1.6, 1.6-1.99, 2.0-2.59, 2.6-2.99, and ≥3.0). Correlation of endpoints with anticoagulation intensities was analyzed with INR at the time of events or at the end of follow-up. The time in therapeutic range (TTR) was determined with the method of Rosendaal et al. 16 For this determination, the target INR level was set at 1.6-2.6 for patients aged 70 years or older, and at 2.0-3.0 for patients aged younger than 70 years, following the Japanese guidelines. 14 
Statistical Analysis
Data are presented as mean ± standard deviation or median, if necessary. The statistical significance of differences in the mean values was analyzed using Student's t-test or analysis of variance, in the median values using the Mann-Whitney U-test or Kruskal-Wallis test, as appropriate. Frequencies of parameters or events were compared using the chi-square test or Fisher's exact test, as appropriate. Event-free rates of thromboembolism and major hemorrhage between the primary and secondary prevention groups were compared using the KaplanMeier method and log-rank test. A Cox proportional hazard model was used to examine whether a history of stroke/ TIA was an independent risk factor for the events in a crude model (Model 1) and after adjustment for confounding factors, including the other components of CHADS2 (Model 2) and CHA2DS2-VASc scores (additionally, vascular disease [coronary artery disease], age 65-74 years, and female sex: Model 3), and warfarin and antiplatelet use (Model 4). To clarify the optimal INR level, a multivariate logistic regression analysis was performed. Two-sided P values less than .05 were considered to be statistically significant. All statistical analyses were performed with the IBM SPSS Statistics version 23.0 (IBM Corporation, Somers, NY).
Results
Of the 7937 patients with AF who had been enrolled in the J-RHYTHM Registry, 421 patients were excluded because they had valvular AF. Of the remaining 7516 patients with NVAF, 110 (1.5%) were lost to follow-up. Therefore, a total of 7406 patients with NVAF, that is, 6384 patients without and 1022 patients with a history of ischemic stroke/TIA, were eligible for the present analyses.
Baseline Characteristics and the Status of Antithrombotic Therapy
Baseline clinical characteristics and antithrombotic therapy at the time of enrollment are summarized in Tables 1 and   Table 1 2, respectively. Mean age and the prevalence of male sex, diabetes mellitus, and coronary artery disease were higher in the secondary than in the primary prevention group. It was a matter of course that the CHADS2 score was 2 or higher in all patients of the secondary prevention group, giving a higher mean CHADS2 score of 3.5 ± 1.0, as compared with the primary prevention group ( Table 1) . The frequency of warfarin use as well as antiplatelet drugs was higher in the secondary than in the primary prevention group (Table 2) . Mean INR and TTR were slightly but significantly higher in the secondary than in the primary prevention group (Table 2) .
Event Rates and a History of Stroke/TIA
During the 2-year follow-up period, thromboembolic events occurred in 126 patients (1.7%), major hemorrhage in 140 (1.9%), and all-cause death in 195 (2.6%), including cardiovascular death in 68 (.9%). The overall incidence of thromboembolism was significantly higher in the secondary than in the primary prevention group (2.8% versus 1.5%, P = .004). The incidence rate of major hemorrhage was also higher in the secondary than in the primary prevention group (3.0% versus 1.7%, P = .006). All-cause mortality was higher in the secondary than in the primary prevention group (3.9% versus 2.4%, P = .008), whereas cardiovascular mortality was comparable between the groups (1.0% versus .9%, P = .967). The KaplanMeier curves for endpoints are shown in Figure 1 . Eventfree rates of thromboembolism, major hemorrhage, and all-cause death in the secondary prevention group were significantly lower than those in the primary prevention group (P = .002, P = .003, and P = .004 by log-tank test, respectively; Fig 1, A-C) . Cardiovascular mortality was comparable between the groups (Fig 1, D) . As a whole group, hazard ratios (HRs) of a prior ischemic stroke/ TIA for thromboembolism remained significantly high even in the most critical adjusting model (HR 1.82, P = .006 in Model 4). Although the HR for major hemorrhage in Model 4 did not reach statistical significance (HR 1.49, P = .055), HRs for combined events of thromboembolism plus major hemorrhage were consistently high even after adjustment for multiple confounding factors (HR 1.64, P = .001 in Model 4; Table 3 ). The HRs for allcause death were significantly high in only the crude model (Model 1) and after adjustment for CHADS2 score (Model 2), whereas those for cardiovascular death were similar in any model. These results indicated that a history of ischemic stroke/TIA was an independent risk factor for thromboembolism and for combined events of thromboembolism and major hemorrhage (Table 3) .
Event Rates and Warfarin Use
The characteristics of patients in the nonwarfarin and warfarin groups and 5 INR subgroups are summarized in Table 4 . Twenty patients, including 18 without information on warfarin use and 2 lacking INR values at the end of follow-up, were excluded. Consequently, the remaining 7386 patients were used for post hoc analyses requiring INR values at the end of follow-up. In the primary prevention group, prevalence of all components of CHADS2 score except for prior stroke/TIA in patients on warfarin was higher than that in the nonwarfarin group, resulting in a higher CHADS2 score in patients on warfarin. By contrast, in the secondary prevention group, prevalence of patients aged 75 years or older and those with diabetes mellitus in the nonwarfarin group was higher than Abbreviations: INR, international normalized ratio of prothrombin time; SD, standard deviation; TTR, time in therapeutic range. Data are number of patients (%) or mean ± SD. *Comparison between primary and secondary prevention groups. **Target INR, 2.0-3.0 (<70 years) or 1.6-2.6 (≥70 years). that in patients on warfarin, resulting in a higher CHADS2 score in the nonwarfarin group than in patients on warfarin (Table 4) . Rates of thromboembolism and all-cause death were significantly higher in the secondary than in the primary prevention group (8.7% versus 2.5%, P = .002; and 17.5% versus 5.8%, P < .001, respectively), when warfarin was not given (Table 5) . However, the rate of thromboembolic events was significantly lower in the warfarin group than in the nonwarfarin group, especially in the secondary prevention group (Fig 2, A) . By contrast, rates of major hemorrhage in patients with and without warfarin were not different in either the primary or secondary prevention group (Fig 2, B) . All-cause and cardiovascular mortality showed similar trends to that of thromboembolism (Fig 2, C,D) .
Figure 1. Event-free curves for thromboembolism (A), major hemorrhage (B), all-cause death (C), and cardiovascular death (D) in the primary
In patients who received warfarin, cerebral infarction occurred eventually in 54 (1.0%/2 years) and 19 (2.1%/2 years) patients in the primary and secondary prevention groups, respectively (Table 5) , including typical cardiogenic embolism in 18 and 7, atherothrombotic stroke in 5 and 2, lacunar infarction in 3 and 1, and undetermined in others.
Event Rates in INR Subgroups
Incidence rates of thromboembolism for both the primary and secondary prevention groups showed an obvious decreasing trend among the nonwarfarin group and 5 INR subgroups of patients receiving warfarin (P < .001 for trend in both groups, Table 5 ). Rates of major hemorrhage for both prevention groups also showed an apparent increasing trend among the nonwarfarin group and 5 INR subgroups in patients receiving warfarin (P < .001 and P = .009 for trend, respectively; Table 5 ). Consequently, the combined rates of thromboembolic and major hemorrhagic events were lower at INR levels of 1.6-2.59 in both prevention groups (Table 5 ). All-cause mortality was lower in patients on warfarin than in those without warfarin for both prevention groups (Table 5 ). This trend was negated at INR levels of 3.0 or higher in both prevention groups. Odds ratios (ORs) for thromboembolism were significantly lower in INR subgroups of 1.6-1.99 and 2.0-2.59 than in the nonwarfarin group, even after adjustment for confounding factors, in both the primary and secondary prevention groups (Table 6 ). By contrast, the significance of ORs for major hemorrhage in INR subgroups disappeared after adjustment for confounding factors in the secondary prevention group (Table 6) . Consequently, ORs for thromboembolism plus major hemorrhage were significantly lower in INR subgroups of 1.6-2.59 than in the nonwarfarin group, even after adjustment for confounding factors, in both the primary and secondary prevention groups (Table 6 ). ORs for allcause death were significantly lower in INR subgroups of lower than 3.0 in both prevention groups (Table 6 ).
Event Rates in Age Groups
When the same analyses were performed in 2 age groups of younger than 70 and 70 years or older, rates of thromboembolism were significantly lower in patients taking warfarin than in the nonwarfarin group among patients aged 70 years or older in both the primary and secondary groups (Fig 3, A) . By contrast, the differences did not reach a significant level even in the secondary group, although rates of major hemorrhage appeared to be slightly higher in patients on warfarin in all groups (Fig 3, B) . Abbreviations: INR, international normalized ratio of prothrombin time. Data are odds ratios (95% confidence interval) adjusted for the components of CHA2DS2-VASc score (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, vascular disease [coronary artery disease], age 65-74 years, and female sex) and antiplatelet use, using the nonwarfarin group as a reference.
*At the time of events or at the end of follow-up.
All-cause death and cardiovascular mortality in both age groups showed similar trends to that of thromboembolism (Fig 3, C,D) . Event rates among the nonwarfarin group and 5 INR subgroups are summarized in Table 7 . There were significant trends in rates of thromboembolism and major hemorrhage in all age groups, except for major hemorrhage in patients aged younger than 70 years in the secondary group (Table 7) . ORs for events in each age group and INR subgroup are summarized in Table 8 . In patients aged younger than 70 years in the primary prevention group, ORs for thromboembolism, combined events of thromboembolism plus major hemorrhage, and all-cause death were significantly lower in INR subgroups of 1.6-1.99 and 2.0-2.59, whereas those for major hemorrhage were significantly higher in the INR subgroups of 2.6-3.0 and 3.0 or higher, as compared with the nonwarfarin group (Table 8, A). In patients aged younger than 70 years in the secondary prevention group, OR for all-cause death was significantly lower in only the INR subgroup of 2.0-2.59 because the numbers of patients and events were small (Table 8, B). In patients aged 70 years or older in both the primary and secondary prevention groups, ORs for thromboembolism were significantly lower in the INR subgroups of 1.6-1.99 and 2.0-2.59, and those for combined events of thromboembolism plus major hemorrhage were significantly lower in the INR subgroup of 1.6-1.99 (Table 8 , A,B).
Discussion
There were major findings in the present study. First, as expected, patients with a history of ischemic stroke/ TIA were characterized as a high-risk population, with a CHADS2 score of 3.5 ± 1.0. Second, warfarin was prescribed in approximately 93%, and the TTR, based on the Japanese guidelines, 14 was 62.8% in the secondary prevention group. This indicates that anticoagulation therapy was performed frequently, and the quality of warfarin therapy seemed acceptable among NVAF patients with a history of ischemic stroke/TIA in Japan. 17 However, rates of both thromboembolism and major hemorrhage were higher in the secondary than in the primary prevention group. Prior ischemic stroke/TIA emerged as an independent risk for both events after adjustment for multiple confounding factors. Third, for prevention of thromboembolism, an INR level of 1.6-2.59 would be optimal among Japanese NVAF patients in the secondary as well as in the primary prevention groups.
Efficacy and Safety of Warfarin
Although the use of NOACs is increasing worldwide, 18 the current Japanese guidelines 14 recommend both warfarin and NOACs for the prevention of thromboembolism for patients with NVAF. Warfarin is still used in clinical practice 18 and indicated for NVAF patients who have renal insufficiency and other comorbidities. Therefore, the present results would be practically important even in the era of NOACs.
In the present study, efficacy of warfarin for preventing thromboembolism was apparent in both the secondary and primary prevention groups (Fig 2) . This salutary effect of warfarin was evident particularly in patients aged 70 years or older for both the primary and the secondary prevention of stroke (Fig 3) . Although rates of thromboembolism in patients aged younger than 70 years on warfarin appeared to be lower than in those without warfarin in both the primary and secondary groups, these differences were not statistically significant (Fig 3, A) . As the number of patients and events in each group was small, it could be explained that statistical power was insufficient when patients were divided into 2 prevention groups and an additional 2 age groups. In our previous subanalysis on event rates in age groups in patients with NVAF, 19 there was a significant difference in rates of thromboembolism between patients with and without warfarin even in patients aged younger than 70 years. Therefore, warfarin therapy would be beneficial in preventing thromboembolism even in patients aged younger than 70 years. However, it remains controversial whether warfarin therapy is really beneficial in younger patients aged younger than 65 years because the difference disappeared in younger patients when the cutoff age was 65 years. 19 A metaanalysis of 6 randomized controlled studies on the effects of warfarin in patients with NVAF showed comparable risk reduction of thromboembolism for primary prevention studies (including several % of patients with prior ischemic stroke) and a secondary prevention study, although target INR levels differed among the studies. 20 The European Atrial Fibrillation Trial 21 was a secondary prevention study with 1007 NVAF patients to determine the efficacy of warfarin and aspirin. The target INR level was set at 2.5-4.0, and aspirin was given at a dose of 300 mg. Warfarin was effective at preventing thromboembolic events, as compared to aspirin (HR .38, P < .001) and placebo (HR .34, P < .001). However, warfarin was associated with major hemorrhage more frequently (2.8%/year), as compared with aspirin (.9%/year) and placebo (.7%/year). In our secondary prevention group, somewhat different results were observed; overall, warfarin was associated with a significantly lower incidence of thromboembolic events (2.2%/2 years), but not with a higher incidence of major hemorrhage (3.2%/2 years). This could be attributed to lower INR levels in the secondary prevention group in the present study (1.97 ± .48).
Target Anticoagulation Intensity for Secondary Prevention
Current guidelines in Western countries for management of patients with AF recommend the same INR Abbreviations: INR, international normalized ratio of prothrombin time. Data are odds ratios (95% confidence interval) adjusted for the components of CHA2DS2-VASc score (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, vascular disease [coronary artery disease], age 65-74 years, and female sex) and antiplatelet use, using the nonwarfarin group as a reference.
*At the time of events or at the end of follow-up. levels for the primary and secondary prevention of thromboembolism in NVAF patients with and without prior ischemic stroke/TIA. 22, 23 In the Japanese guidelines, 14 target INR levels of 1.6-2.6 are recommended for patients aged 70 years or older; this is based on results of the secondary prevention study by Yasaka et al 10 and the J-RHYTHM Registry. 13 Concentration of D-dimer as an index of fibrinolytic activity and prothrombin fragment F1+2 as an index of coagulation activity was not different between INR levels of 1.5-1.9 and 2.0 or higher in Japanese patients with NVAF. 24 This indicated that slightly lower anticoagulation intensities of warfarin could be effective at inhibiting prothrombotic activity in Japanese patients with NVAF.
NVAF patients with prior ischemic stroke/TIA are at higher risk for thromboembolism than those without prior ischemic events, and therefore anticoagulation therapy is indicated. One might ask whether higher INR values would be required for prevention of thromboembolism in the secondary prevention group as compared to the primary prevention group, but this was not the case. An INR level of 1.6-2.59 would be optimal for prevention of thromboembolism in the secondary as well as in the primary prevention group among Japanese NVAF patients.
The frequency of intracranial hemorrhage on warfarin therapy with a target INR level of 2.0-3.0 was 4-fold higher in Asian than in Caucasian patients. 25 Suzuki et al 26 also showed that INR levels of 2.27 or higher were associated with an increased risk of major hemorrhage in Japanese patients with NVAF. The present results showing that INR levels of 2.6 or higher were associated with higher rates of major hemorrhage are consistent with prior results.
25,26
Study Limitations
The present study had several limitations. First, it was performed in a single country and the subjects were enrolled in only 158 institutions in Japan. Because most participating physicians were cardiologists, the patients' clinical backgrounds might not be extrapolated to a general Japanese patient population with NVAF. Therefore, generalizing from the present results of this specific population to individual clinical situations should be done carefully. Second, although this registry was relatively large, analyzing a total of 7406 patients with NVAF, the numbers of patients and events in INR subgroups were small especially in the secondary prevention group. This might have reduced the statistical power of the present study. Third, because the study design was prospective but observational, antithrombotic treatments with warfarin or antiplatelet agents were not randomized. Dosage of warfarin and clinical targets of INR levels for individual patients were selected at the discretion of treating physicians. Fourth, 1.5% of patients were lost to follow-up in the present study, which could have led to the underreporting of endpoints. Finally, the present study had been performed before NOACs were approved for clinical use in Japan. Therefore, the present results should be interpreted carefully in the era of NOACs.
Conclusions
Both thromboembolism and major hemorrhage occurred more frequently in NVAF patients with prior stroke/ TIA even when TTR was higher as compared with those without prior stroke/TIA. A history of ischemic stroke/ TIA is an independent risk factor for both events. Anticoagulation therapy with warfarin was performed frequently for the secondary prevention of stroke in Japan and could have a reducing effect for thromboembolism. An INR level of 1.6-2.59 would be optimal for preventing thromboembolism and for avoiding major hemorrhage in Japanese NVAF patients for the secondary as well as primary prevention of thromboembolism.
